Machine learning identifies a core gene set predictive of acquired resistance to EGFR tyrosine kinase inhibitor
Acquired resistance (AR) to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) is a major issue worldwide, for both patients and healthcare providers. However, precise prediction is currently infeasible due to the lack of an appropriate model. This study was conducted to develop and validate an individualized prediction model for automated detection of acquired EGFR-TKI resistance.
Penalized regression was applied to construct a predictive model using publically available genomic cohorts of acquired EGFR-TKI resistance. To develop a model with enhanced generalizability, we merged multiple cohorts then updated the learning parameter via robust cross-study validation. Model performance was evaluated mainly using the area under the receiver operating characteristic curve.
Using a multi-study-derived machine learning method, we developed an extremely parsimonious model with generalized predictors (DDK3, CPS1, MOB3B, KRT6A), which has excellent prediction performance on blind cohorts for AR to EGFR-TKIs (gefitinib, erlotinib and afatinib) and monoclonal antibody against EGFR (cetuximab). In addition, our model also showed high performance for predicting intrinsic resistance (IR) to EGFR-TKIs from two large-scale pharmacogenomic resources, the Cancer Genome Project and the Cancer Cell Line Encyclopedia, suggesting that these general predictive features may work across AR and IR.
We successfully constructed a multi-study-derived prediction model for acquired EGFR-TKI resistance with excellent accuracy, generalizability and transferability.
KeywordsEpidermal growth factor receptor Protein tyrosine kinases Drug resistance Transcriptomics Computer modeling
This paper was supported by Konkuk University in 2015.
SYK and YRK conceived, designed the experiments and performed and analyzed the experiments. SYK performed the mathematical and statistical analyses. All authors wrote the paper. All authors analyzed the results and approved the final version of the article.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
No human participants were used in this study.
- Eberlein CA, Stetson D, Markovets AA et al (2015) Acquired resistance to the mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical models. Cancer Res 75:2489–2500. https://doi.org/10.1158/0008-5472.CAN-14-3167 CrossRefPubMedPubMedCentralGoogle Scholar
- Wood ER, Truesdale AT, McDonald OB et al (2004) A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 64:6652–6659. https://doi.org/10.1158/0008-5472.CAN-04-1168 CrossRefPubMedGoogle Scholar